Payment overview · 2025
General Payments
$263.73
13 reported records · 6 companies
Healthcare provider profile · identity verified
Charles Wesley Minor
Allopathic & Osteopathic Physicians|Family Medicine · DORA, AL · NPI 1700405503
Verified facts
What the public records show
CMS Open Payments records show Charles Wesley Minor received $263.73 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.97 | 42.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.36 | 19.5% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $31.95 | 12.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.84 | 11.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.70 | 7.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.91 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.73 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.97 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.97 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $31.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 582 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 203 | 76 |
| Gabapentin | Gabapentin | 190 | 53 |
| Losartan Potassium | Losartan Potassium | 189 | 67 |
| Omeprazole | Omeprazole | 176 | 68 |
| Lisinopril | Lisinopril | 165 | 55 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 159 | 137 |
| Tramadol Hcl | Tramadol Hcl | 153 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 49 |
| Clonazepam | Clonazepam | 149 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 50 |
| Meloxicam | Meloxicam | 142 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 26 |
| Alprazolam | Alprazolam | 107 | 25 |
| Metformin Hcl | Metformin Hcl | 106 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 33 |
| Methocarbamol | Methocarbamol | 88 | 42 |
| Potassium Chloride | Potassium Chloride | 87 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 30 |
| Simvastatin | Simvastatin | 79 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 76 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 71 | 59 |
| Montelukast Sodium | Montelukast Sodium | 69 | 27 |
| Mounjaro | Tirzepatide | 69 | 11 |
| Fluconazole | Fluconazole | 66 | 44 |
| Sertraline Hcl | Sertraline Hcl | 65 | 20 |
| Glimepiride | Glimepiride | 64 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 22 |
| Prednisone | Prednisone | 64 | 46 |
| Furosemide | Furosemide | 63 | 27 |
| Trulicity | Dulaglutide | 59 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 20 |
| Trazodone Hcl | Trazodone Hcl | 58 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 21 |
| Azithromycin | Azithromycin | 56 | 49 |
| Celecoxib | Celecoxib | 56 | 32 |
| Lorazepam | Lorazepam | 56 | 13 |
| Ozempic | Semaglutide | 56 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 30 |
| Famotidine | Famotidine | 52 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 44 |
| Cefdinir | Cefdinir | 49 | 45 |
| Farxiga | Dapagliflozin Propanediol | 48 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 18 |
| Carvedilol | Carvedilol | 44 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 17 |
| Atenolol | Atenolol | 41 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 17 |
| Cephalexin | Cephalexin | 40 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 16 |
| Ondansetron Odt | Ondansetron | 39 | 26 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 14 |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Mupirocin | Mupirocin | 35 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Pregabalin | Pregabalin | 34 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 15 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 26 |
| Temazepam | Temazepam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Eliquis | Apixaban | 26 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 17 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.73 · 13 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, JARDIANCE, Ozempic, REXULTI, Rybelsus, SUBLOCADE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error